학술논문
Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non‐canonical FLT3 mutation: A proof of concept.
Document Type
Article
Author
Source
Subject
*ACUTE myeloid leukemia
*PROOF of concept
*GENETIC mutation
*
*
Language
ISSN
0007-1048
Abstract
Besides I FLT3 i conventional mutations, non-canonical mutations clustering in the I FLT3 i -JMD have also been described. (A) Evaluation of the clinical history of our AML patient who showed a FLT3 deletion (F590 R595) at diagnosis and achieved complete remission 2 months after starting treatment. To the Editor, The Fms-like tyrosine kinase 3 ( I FLT3 i ) represents one of the most frequently mutated gene in acute myeloid leukaemia (AML), accounting for approximately 30% of de novo cases. Blast cells isolated from FLT3 wild-type and FLT3-ITD AML samples were used as negative and positive controls for protein expression levels of FLT3 signalling, respectively. [Extracted from the article]